Compare Howmet Aerospace Inc (HWM) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Howmet Aerospace (HWM) trades at $225.24, up 1.14% with strong fundamental performance including three consecutive quarterly earnings beats. The stock shows bearish technical signals despite robust profitability metrics with 20.52% net income margin and 34.89% ROE. Recent news highlights defense aerospace strength and upcoming Q3 2026 earnings announcement on October 29, 2026.

Analyst consensus remains strongly bullish with 84% buy ratings and $328.10 price target representing 46% upside potential. Key risks include technical weakness, valuation multiples above industry averages, and dependence on aerospace sector recovery. The combination of strong fundamentals and analyst optimism suggests potential for recovery from current technical pressure.

Regeneron Pharmaceuticals (REGN) trades at $739.57, down 0.34% with a bearish technical signal. The company maintains strong fundamentals with a 27.86% net income margin and consistent earnings beats. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront payments and milestone potential. Cash flow improved significantly in 2025 with $635 million net cash flow versus negative flows in prior years.

The stock presents a compelling investment case with strong profitability, positive analyst sentiment (69% buy ratings), and a $849.84 consensus price target offering 15% upside. Key risks include competitive pressures in ophthalmology drugs and reliance on key partnerships. The expanded Sanofi collaboration and promising clinical pipeline provide catalysts for growth.